Constipation Clinical Trial
Official title:
Influence of the Consumption of Milk Drink With Bifidobacterium Animalis in Symptoms of Constipation.
Constipation is a disorder which can be associated with various pathologies or could also be an effect of the consumption of drugs, improper diet and life style. Is increasingly common the utilization of probiotics in foods. Probiotics are defined as live microorganisms administered in adequate amounts confer a health benefit to the host, the most widely used for milk-based drinks are lactic bacteria Lactobacillus and Bifidobacterium. The objective of the present study is to assess the effectiveness of the consumption of dairy beverage enriched with probiotic for the treatment of the symptoms of constipation.
To that randomized clinical trial, double blind controlled, were recruited in the city of
Teutônia - RS - Brazil, 49 women aged 20-50 years. Patients with pathologies that alter the
bowel habits, such as food allergies and intolerances; diabetic women, pregnant,
breastfeeding women, gastrointestinal symptoms, gastrointestinal pathologies preliminary,
current or recent use of antibiotics, anti-inflammatory, laxatives or other drugs were
excluded. Ulcerative colitis, Crohn's disease and irritable bowel syndrome, patients having
lactose intolerance or do not like milk drink, besides patients showing them to use other
types of probiotic food, prebiotic and symbiotic.
Study participants have been diagnosed with constipation according to the recommendations
established by the Rome III criteria (World Gastroenterology Organization) and the Bristol
Scale (World Gastroenterology Organization). Answered to a questionnaire on the general
data, with questions related to the consumption of fruits and vegetables, meats, milk
products, water intake, alcohol intake, smoking and physical activity practice.
Were randomly divided in two groups, one group received probiotic culture dairy drink
(intervention group), animalis bifidobacterium, containing 3.2 x 107 and the other group has
received dairy drink (control group). Was directed towards participants the consumption of
one cup (150 ml) of dairy drink per day, preferably on an empty stomach or morning snack,
during period of 60 days. The dairy beverages have been donated by a company, bottled in 1
liter bottles, transported in appropriate thermal boxes and delivered in three stages, every
twenty days in the residence of the participants.
After 60 consumption days of dairy beverage new reviews with the participants were
conducted, they are nutritional assessment and implemented the Rome III Criteria and Scale
Bristol again. To do this the weight, height, waist and hip circumference were measured. To
measure was utilized digital balance with capacity of 300 kg and inelastic tape with an
extension of 1.5 m. Was recommended for participants to stay barefoot and use light
clothing. Thereafter, we calculated the Body Mass Index (BMI), waist-hip ratio and risk for
cardiovascular disease, classified according to the parameters established by the World
Health Organization (1998).
The guidelines on how consume and storing the dairy drink were provided to the participants
before the distribution of products. A dairy beverage should be consumed every day
preferentially in the morning, be agitated before consuming, not heat it, stored
refrigerated. During the study period, participants were instructed not to change their
eating habits, physical activity practice, fluid intake and not make use of other products
with probiotic culture.
Quantitative variables were described using mean and standard deviation or median and
interquartile range. Categorical variables were described by absolute and relative
frequencies. To compare means between groups, Student's t-test for independent samples was
applied. In case of asymmetry, the Mann-Whitney test was used. To compare proportions, the
chi-square test was applied. To evaluate the ROME III and Bristol-scale pre-and
post-intervention, the Wilcoxon test was applied. Data analysis was performed using the
Statistical Package for Social Sciences (SPSS) version 18.0. The level of statistical
significance was 5% (p ≤ 0.05).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 |